Combo ‘Polypill’ May Cut Heart Attack, Stroke Risk Up to 40%
The Pharma Data
NOVEMBER 16, 2020
Yang pointed out that “the fact that it’s generic is a double-edged sword, because no big pharma company is willing to invest a lot of money in developing and marketing a polypill. It may require either health insurance companies or governments or charitable organizations to develop polypills.”
52 
Let's personalize your content